{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:54:30Z","timestamp":1791500070907,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.oret.2026.09.029","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:36:38Z","timestamp":1791387398000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Neovascular Age-Related Macular Degeneration in Routine US Clinical Practice: Impact of Delayed Treatment Initiation"],"prefix":"10.1016","author":[{"suffix":"III","given":"John D.","family":"Pitcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-6374","authenticated-orcid":false,"given":"Fabiana Q.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Moini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-575X","authenticated-orcid":false,"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-3378","authenticated-orcid":false,"given":"Andrew A.","family":"Moshfeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.oret.2026.09.029_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib4","first-page":"88","article-title":"Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan","volume":"31","author":"Saundankar","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"14","key":"10.1016\/j.oret.2026.09.029_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.oret.2026.09.029_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.oret.2026.09.029_bib7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.oret.2026.09.029_bib8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12886-017-0514-3","article-title":"Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study","volume":"17","author":"Elshout","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"10.1016\/j.oret.2026.09.029_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017771","article-title":"Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study","volume":"7","author":"Sim","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00417-012-2038-0","article-title":"Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration","volume":"251","author":"Muether","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1755-3768.2011.02268.x","article-title":"Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment","volume":"91","author":"Bloch","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.oret.2026.09.029_bib13","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00417-013-2338-z","article-title":"Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010","volume":"251","author":"Cohen","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.oret.2026.09.029_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.oret.2026.09.029_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/aos.12781","article-title":"Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration","volume":"93","author":"Rasmussen","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2026.09.029_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114368","article-title":"Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome","volume":"160","author":"Martinez-Castillo","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.oret.2020.09.025","article-title":"Principal cause of poor visual acuity after neovascular age-related macular degeneration: age-related eye disease study 2 report number 23","volume":"5","author":"Okeagu","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"10.1016\/j.oret.2026.09.029_bib18","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e3182018df6","article-title":"Time to first treatment: the significance of early treatment of exudative age-related macular degeneration","volume":"32","author":"Rauch","year":"2012","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.oret.2026.09.029_bib19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","article-title":"Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration","volume":"153","author":"Lim","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.oret.2026.09.029_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","article-title":"Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment trial","volume":"138","author":"Ramakrishnan","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"10.1016\/j.oret.2026.09.029_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"10.1016\/j.oret.2026.09.029_bib22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","article-title":"Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records","volume":"127","author":"Kiss","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.oret.2026.09.029_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/2474126420960896","article-title":"Visual acuity outcomes in patients receiving frequent treatment of neovascular age-related macular degeneration in clinical practice","volume":"5","author":"Moshfeghi","year":"2020","journal-title":"J Vitreoretin Dis"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"10.1016\/j.oret.2026.09.029_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.oret.2026.09.029_bib29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.09.029_bib30","unstructured":"American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern. https:\/\/www.aao.org\/education\/preferred-practice-pattern\/age-related-macular-degeneration-ppp; 2019. Accessed October 17, 2024."},{"issue":"4","key":"10.1016\/j.oret.2026.09.029_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: A mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/IAE.0000000000001150","article-title":"Neovascular age-related macular degeneration with advanced visual loss treated with anti-vascular endothelial growth factor therapy: clinical outcome and prognostic indicators","volume":"37","author":"Vogel","year":"2017","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.oret.2026.09.029_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/aos.15094","article-title":"What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register","volume":"100","author":"Lovestam Adrian","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12886-023-03021-0","article-title":"Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes","volume":"23","author":"Akkan Aydogmus","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2026.09.029_bib36","article-title":"Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration [preprint]","author":"Zur","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.oret.2026.09.029_bib37","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41433-021-01487-0","article-title":"Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations","volume":"35","author":"Kodjikian","year":"2021","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.oret.2026.09.029_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100318","article-title":"Progression of geographic atrophy: retrospective analysis of patients from the IRIS\u00ae Registry (Intelligent Research in Sight)","volume":"3","author":"Rahimy","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"2","key":"10.1016\/j.oret.2026.09.029_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.eye.6703053","article-title":"Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss","volume":"23","author":"Arias","year":"2009","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.oret.2026.09.029_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-4182(05)80074-2","article-title":"Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration","volume":"40","author":"Oliver-Fernandez","year":"2005","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.oret.2026.09.029_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000239236","article-title":"Time between symptom onset and assessment in age-related macular degeneration with subfoveal choroidal neovascularization","volume":"224","author":"Schalnus","year":"2010","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1016\/j.oret.2026.09.029_bib42","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00417-014-2885-y","article-title":"Rate of vision loss in neovascular age-related macular degeneration explored","volume":"253","author":"Real","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2026.09.029_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: The need for a change of mindset","volume":"243","author":"Mones","year":"2020","journal-title":"Ophthalmologica"},{"issue":"8","key":"10.1016\/j.oret.2026.09.029_bib44","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/eye.2016.90","article-title":"Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study","volume":"30","author":"Holz","year":"2016","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026005191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026005191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:57Z","timestamp":1791499437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026005191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S2468653026005191"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.09.029","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Neovascular Age-Related Macular Degeneration in Routine US Clinical Practice: Impact of Delayed Treatment Initiation","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology, Inc.","name":"copyright","label":"Copyright"}]}}